What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's biggest scorchers.


Jan. 13 Weekly Gain My Watchlist
Idenix Pharmaceuticals (Nasdaq: IDIX) $14.42 105% Add
Georgia Gulf (NYSE: GGC) $32.93 53% Add
Trina Solar (NYSE: TSL) $9.57 41% Add
Suntech Power (NYSE: STP) $2.96 29% Add
Quepasa (AMEX: QPSA) $3.78 24% Add

Source: Barron's.

Idenix was the market's biggest loser, more than doubling on buyout speculation. This is the kind of buzz that rarely moves a stock this high, but major pharmaceuticals, fearing patent expirations for their aging blockbusters, have been scooping up promising biotechs at a feverish pace lately. Idenix -- as a result of its potentially huge hepatitis-C treatment -- is one of the more compelling biotechs still single.

There was no speculation behind Georgia Gulf's 53% spike. There was a hostile takeover bid made on the company. The $1.03 billion offer may not be enough, given the way the stock zoomed past the $30-a-share buyout price. This should be an interesting story to watch in the coming days.

Trina Solar and Suntech Power took off along with many of their solar-energy peers. The volatile sector was slammed in 2011, but it's off to a strong start in 2012 on the hopes that global turmoil subsides and countries begin dedicating themselves to clean energy initiatives.

Finally we have Quepasa starting to happen for bulls after a brutal 2011. The parent company of myYearbook and the smaller namesake Spanish-language social site hired a new communications and public-relations chief. Quepasa also announced that it will make a presentation at the BOCEMb 2012-Noble Financial Capital Markets' Eight Annual Equity Conference this Wednesday.

It was a great week for these five stocks. If you want to get an early read on some of tomorrow's major gainers, there's a special report on three hidden winners in a booming industry. The report is free -- like this article -- but it won't be around forever, so check it out now.

Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Longtime Fool contributor Rick Munarriz calls them as he sees them. He owns no shares in any of the stocks in this story and is also part of the Rule Breakers newsletter research team, seeking out tomorrow's ultimate growth stocks a day early. The Motley Fool has a disclosure policy.